CAR T engineering moves from oncology into chronic non-malignant disease
CAR T-cell therapy has spent the last decade rewriting hematologic oncology by combining precise antigen recognition with sustained cellular killing. The new review from Signal Transduction and Targeted Therapy argues that the same logic can be redirected toward chronic non-malignant diseases driven by persistent pathological cells rather than by transformed tumor clones. In that framing, the target is no longer only cancer. It is the long-lived cellular machinery that keeps infection, autoimmunity, fibrosis, alloimmunity, and senescence alive despite conventional treatment.
The appeal is mechanistically straightforward. Many chronic disorders depend on cells that sit upstream of ongoing tissue injury: infected reservoirs that escape immune surveillance, autoreactive B cells and plasma cells that keep producing pathogenic antibodies, fibroblasts that sustain scarring, and senescent cells that alter tissue niches through inflammatory signaling. A programmable T cell can be built to recognize those populations with a specificity that conventional immunosuppression rarely achieves. The review presents this as a platform technology rather than a single-disease intervention, with the same core engineering principles adapted to sharply different biologic problems.
One sentence captures the field’s central gamble: durable cell therapy may finally match the durability of the disease itself.
Antigen choice, persistence, and the need to survive hostile tissue biology
The review places heavy emphasis on the design elements that determine whether a CAR product can function outside oncology. Co-stimulatory domains such as CD28, 4-1BB, and OX40 shape expansion, persistence, and effector strength. In chronic inflammatory settings, where target cells may sit inside suppressive or fibrotic microenvironments, standard activation is often not enough. The inclusion of PD-1-CD28 switch receptors is meant to reverse inhibitory checkpoint signaling, while cytokine-resistant constructs such as CARs incorporating dominant-negative TGF-β receptors are designed to keep engineered cells active in hostile tissue niches.
These modifications are not technical ornamentation. They are the difference between a CAR that briefly circulates and one that can keep pressure on disease-maintaining cell populations long enough to alter the biology of relapse and reactivation. In cancer, that persistence matters because malignant clones rebound when surveillance fades. In non-malignant disease, persistence matters for a different reason: the pathogenic compartment may be dispersed, partially protected, and biologically entrenched over years. The review repeatedly returns to this challenge, especially where the intended target is embedded in inflamed tissue rather than in blood.
HIV, EBV, and the logic of persistent reservoir clearance
Chronic infection is one of the clearest use cases for CAR-based therapy beyond oncology. The review discusses HIV and EBV as examples where the therapeutic goal is to identify and eliminate reservoirs that conventional antivirals or supportive care do not eradicate. In those settings, the promise of CAR T cells lies in redirecting cytotoxicity against cells that harbor viral material or sustain reactivation cycles. The biologic argument is compelling: as long as a reservoir persists, suppression rather than cure remains the best-case outcome.
This is also where the field confronts its most unforgiving constraints. Viral reservoirs can be small, anatomically hidden, and heterogeneous in antigen expression. If the target antigen is absent from enough reservoir cells, selective pressure may fall short of eradication. If the antigen is too broadly expressed, safety becomes the dominant concern. The review treats that balance as central to translating preclinical success into durable remission. In infectious disease, the difference between a useful response and a dangerous one can hinge on whether engineered cytotoxicity is narrowly aimed at reservoir-bearing cells or diffuses into healthy compartments.
Autoimmunity shifts the target from suppression to depletion or regulation
Autoimmune disease is presented through two distinct strategies: depletion of pathogenic CD19– or BCMA-expressing B-lineage cells, and immune reprogramming through CAR-engineered regulatory T cells (CAR-Tregs). The depletion model is familiar to hematology, but the review places it in a new context. Here, the target is not a malignant clone; it is the antibody-producing and antigen-presenting machinery that perpetuates self-reactivity. By removing those cells, CAR therapy may interrupt the cycle of autoantibody production, antigen presentation, and tissue injury that keeps systemic disease active.
CAR-Tregs go a step further. Rather than destroying a target population, they are designed to restore local immune tolerance. That approach is particularly relevant in organs where broad immunosuppression is costly and incomplete. The review cites early clinical experiences in systemic lupus erythematosus, systemic sclerosis, myositis, and multiple sclerosis, where feasibility has already been demonstrated in human disease. The value of these early studies is not simply proof that infusion is possible. It is evidence that engineered immune cells can be deployed in settings where immune balance, not tumor clearance, is the therapeutic endpoint.
A second sentence deserves emphasis: for autoimmune disease, the ideal CAR may be regulatory rather than destructive.
Fibrosis, hemophilia, transplantation, and senescence expand the target list
The review extends the platform into several other disease states with distinct biology. In fibrosis, fibroblast activation protein (FAP) is discussed as a target on activated fibroblasts, cells that help maintain the matrix remodeling and tissue stiffening that define progressive scarring. If those cells can be selectively removed or reprogrammed, the tissue environment may become less permissive to ongoing fibrosis. The logic is attractive because fibrosis is often self-reinforcing: once activated fibroblasts establish the niche, they can keep it going.
In hemophilia, the target is not the clotting factor itself but the immune response against it. The review describes B-cell antibody receptor (BAR)-CARs aimed at factor VIII and factor IX inhibitors, a strategy intended to erase the immune cells responsible for neutralizing replacement therapy. Transplantation adds another layer, with HLA-specific CAR-Tregs proposed to promote graft tolerance without blanket immunosuppression. These applications move the field into areas where the clinical goal is durable immune accommodation rather than elimination.
Senescence-associated disease may be the broadest horizon of all. Targets such as uPAR and NKG2DLs reflect a desire to eliminate cells that no longer divide normally but continue to shape tissue biology through pro-inflammatory and pro-remodeling signals. In this setting, a senescent cell is not inert. It is a signaling node that can alter neighboring cells, sustain inflammation, and influence repair. A CAR product aimed at these cells could, in theory, reset the local environment before irreversible damage accumulates.
The translational barrier is specificity, safety, and tissue access
Every application in the review collides with the same translational barriers, even when the diseases differ. Antigen selection must be precise enough to avoid off-target injury, but broad enough to catch the relevant pathogenic compartment. Engineered cells must persist long enough to matter, yet not so long that they create prolonged toxicity. They must also function in tissues that are often inflamed, fibrotic, or immunosuppressive, where trafficking and expansion can fail before the therapeutic target is reached.
These are not abstract engineering problems. They define whether CAR-based therapy remains an oncology export or becomes a general immune platform for chronic disease. The review makes clear that early human experience has already moved beyond speculation in several autoimmune conditions, while preclinical data in infection and fibrosis continue to widen the list of plausible indications. What remains unresolved is how to standardize these products across diseases whose target cells, tissue compartments, and risk profiles differ so sharply.
A platform with breadth, but not yet a settled clinical map
The strongest message from the review is not that CAR T cells belong in every chronic disease. It is that the platform is adaptable enough to justify serious disease-by-disease development where a persistent pathological cell population can be defined. That includes reservoirs in chronic infection, autoreactive B-cell and plasma-cell lineages in autoimmunity, activated fibroblasts in fibrosis, immune clones in transplantation, and senescent cells in age-related pathology.
The unanswered question is not whether engineered cellular therapy can be redirected beyond cancer. It already has been. The harder question is which diseases have the cleanest biological target, the safest on-target effect, and the most realistic path to durable remission rather than transient suppression. The next phase will depend less on conceptual enthusiasm and more on whether these constructs can be made selective, persistent, and controllable enough for routine clinical use.